Ramesh K. Ramanathan
Molecular Therapeutics/Drug Discovery Program
Biostatistics Department
Graduate School of Public Health
and Biostatistics Facility
USA
Name/email consistency: high
- Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Ramanathan, R.K., Trump, D.L., Eiseman, J.L., Belani, C.P., Agarwala, S.S., Zuhowski, E.G., Lan, J., Potter, D.M., Ivy, S.P., Ramalingam, S., Brufsky, A.M., Wong, M.K., Tutchko, S., Egorin, M.J. Clin. Cancer Res. (2005)